Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.

Hebeda KM, Tzankov A, Boudova L, Saft L, Hasserjian RP, de Boer M, Fend F, Orazi A, Leguit R.

Pathobiology. 2018 Jul 6:1-14. doi: 10.1159/000489678. [Epub ahead of print]

PMID:
29982244
2.

Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma.

Schreuder MI, van den Brand M, Hebeda KM, Groenen PJTA, van Krieken JH, Scheijen B.

J Hematop. 2017 Sep 25;10(3-4):91-107. doi: 10.1007/s12308-017-0302-2. eCollection 2017 Dec. Review.

3.
4.

Platelet CD34 expression and α/δ-granule abnormalities in GFI1B- and RUNX1-related familial bleeding disorders.

Marneth AE, van Heerde WL, Hebeda KM, Laros-van Gorkom BA, Barteling W, Willemsen B, de Graaf AO, Simons A, Jansen JH, Preijers F, Jongmans MC, van der Reijden BA.

Blood. 2017 Mar 23;129(12):1733-1736. doi: 10.1182/blood-2016-11-749366. Epub 2017 Jan 17. No abstract available.

5.

How we do: optimizing bone marrow biopsy logistics for sign-out within 2 days.

de Laak-de Vries I, Siebers AG, Burgers L, Diepenbroek C, Link M, Groenen P, van Krieken JH, Hebeda KM.

J Hematop. 2016 Mar 5;9(2):67-71. eCollection 2016 Jun.

6.

Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.

van den Brand M, Rijntjes J, Hebeda KM, Menting L, Bregitha CV, Stevens WB, van der Velden WJ, Tops BB, van Krieken JH, Groenen PJ.

Histopathology. 2017 Jan;70(2):174-184. doi: 10.1111/his.13015. Epub 2016 Sep 9.

PMID:
27297871
7.

A subset of low-grade B cell lymphomas with a follicular growth pattern but without a BCL2 translocation shows features suggestive of nodal marginal zone lymphoma.

van den Brand M, Balagué O, van Cleef PH, Groenen PJ, Hebeda KM, de Jong D, van Krieken JH.

J Hematop. 2015 Sep 2;9(1):3-8. eCollection 2016 Mar.

8.

Tetraspanin CD37 protects against the development of B cell lymphoma.

de Winde CM, Veenbergen S, Young KH, Xu-Monette ZY, Wang XX, Xia Y, Jabbar KJ, van den Brand M, van der Schaaf A, Elfrink S, van Houdt IS, Gijbels MJ, van de Loo FA, Bennink MB, Hebeda KM, Groenen PJ, van Krieken JH, Figdor CG, van Spriel AB.

J Clin Invest. 2016 Feb;126(2):653-66. doi: 10.1172/JCI81041. Epub 2016 Jan 19.

9.

A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.

Strobbe L, Valke LL, Diets IJ, van den Brand M, Aben K, Raemaekers JM, Hebeda KM, van Krieken JH.

Ann Hematol. 2016 Feb;95(3):417-23. doi: 10.1007/s00277-015-2578-6. Epub 2016 Jan 5.

10.

Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation.

van den Brand M, van der Velden WJ, Diets IJ, Ector GI, de Haan AF, Stevens WB, Hebeda KM, Groenen PJ, van Krieken HJ.

Leuk Lymphoma. 2016 Jul;57(7):1649-56. doi: 10.3109/10428194.2015.1106535. Epub 2015 Dec 23.

PMID:
26694256
11.

Independent development of lymphoid and histiocytic malignancies from a shared early precursor.

Waanders E, Hebeda KM, Kamping EJ, Groenen PJ, Simons A, Hoischen A, Jongmans MC, Hoogerbrugge PM, van Leeuwen FN, Kuiper RP, Te Loo DM.

Leukemia. 2016 Apr;30(4):955-8. doi: 10.1038/leu.2015.193. Epub 2015 Jul 23. No abstract available.

PMID:
26202925
12.

Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma--combined performance of multiple markers.

van den Brand M, Mathijssen JJ, Garcia-Garcia M, Hebeda KM, Groenen PJ, Falini B, Serrano S, van Krieken JH.

Haematologica. 2015 Sep;100(9):e358-60. doi: 10.3324/haematol.2014.120956. Epub 2015 Jun 11. No abstract available.

13.

Microarray-based genomic profiling and in situ hybridization on fibrotic bone marrow biopsies for the identification of numerical chromosomal abnormalities in myelodysplastic syndrome.

Stevens-Kroef MJ, Hebeda KM, Verwiel ET, Kamping EJ, van Cleef PH, Kuiper RP, Groenen PJ.

Mol Cytogenet. 2015 May 28;8:33. doi: 10.1186/s13039-015-0136-5. eCollection 2015.

14.

Immunoglobulin rearrangement analysis from multiple lesions in the same patient using next-generation sequencing.

Appenzeller S, Gilissen C, Rijntjes J, Tops BB, Kastner-van Raaij A, Hebeda KM, Nissen L, Dutilh BE, van Krieken JH, Groenen PJ.

Histopathology. 2015 Dec;67(6):843-58. doi: 10.1111/his.12714. Epub 2015 Jun 26.

PMID:
25891511
15.

Platelet-derived growth factor receptor β (PDGFRβ) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia.

Méhes G, Tzankov A, Hebeda K, Anagnostopoulos I, Krenács L, Bedekovics J.

Histopathology. 2015 Nov;67(5):617-24. doi: 10.1111/his.12704. Epub 2015 May 20.

PMID:
25825163
16.

A "body armor" of leukemia cutis.

Janssen NA, Hebeda KM, Stevens WB, van der Velden WJ.

Am J Hematol. 2015 Aug;90(8):751. doi: 10.1002/ajh.23948. Epub 2015 Feb 25. No abstract available.

17.

Abundance of IgG4+ plasma cells in isolated reactive lymphadenopathy is no indication of IgG4-related disease.

Martinez LL, Friedländer E, van der Laak JA, Hebeda KM.

Am J Clin Pathol. 2014 Oct;142(4):459-66. doi: 10.1309/AJCPX6VF6BGZVJGE.

PMID:
25239412
18.

Sequential immunohistochemistry: a promising new tool for the pathology laboratory.

van den Brand M, Hoevenaars BM, Sigmans JH, Meijer JW, van Cleef PH, Groenen PJ, Hebeda KM, van Krieken JH.

Histopathology. 2014 Nov;65(5):651-7. doi: 10.1111/his.12446. Epub 2014 Aug 6.

PMID:
24766252
19.

Flow cytometric pattern recognition of lymph node biopsies with lymphomas that lack lineage characteristics.

Hebeda K, Preijers F.

Int J Lab Hematol. 2014 Jun;36(3):254-60. doi: 10.1111/ijlh.12229. Review.

PMID:
24750671
20.

[Borrelial lymphocytoma].

Schatorjé EJ, van der Steeg H, Stelma F, Hebeda K, Warris A.

Ned Tijdschr Geneeskd. 2013;157(52):A6605. Dutch.

PMID:
24382037
21.

A dominant-negative GFI1B mutation in the gray platelet syndrome.

Monteferrario D, Bolar NA, Marneth AE, Hebeda KM, Bergevoet SM, Veenstra H, Laros-van Gorkom BA, MacKenzie MA, Khandanpour C, Botezatu L, Fransen E, Van Camp G, Duijnhouwer AL, Salemink S, Willemsen B, Huls G, Preijers F, Van Heerde W, Jansen JH, Kempers MJ, Loeys BL, Van Laer L, Van der Reijden BA.

N Engl J Med. 2014 Jan 16;370(3):245-53. doi: 10.1056/NEJMoa1308130. Epub 2013 Dec 10. Erratum in: N Engl J Med. 2015 Aug 20;373(8):782.

22.

Evaluation of a panel of expert pathologists: review of the diagnosis and histological classification of Hodgkin and non-Hodgkin lymphomas in a population-based cancer registry.

Strobbe L, van der Schans SA, Heijker S, Meijer JW, Mattijssen EJ, Mandigers CM, de Kievit IM, Raemaekers JM, Hebeda KM, van Krieken JH.

Leuk Lymphoma. 2014 May;55(5):1018-22. doi: 10.3109/10428194.2013.827787. Epub 2013 Sep 10.

PMID:
23885798
23.

A "complicated" fracture: a Philadelphia chromosome-positive myeloid sarcoma of the bone.

van Groningen LF, Preijers FW, Jansen JH, Hebeda KM, van der Velden WJ.

Ann Hematol. 2013 Sep;92(9):1287-8. doi: 10.1007/s00277-013-1691-7. Epub 2013 Feb 13. No abstract available.

PMID:
23404583
24.

Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.

van der Voort R, Volman TJ, Verweij V, Linssen PC, Maas F, Hebeda KM, Dolstra H.

Biol Blood Marrow Transplant. 2013 Mar;19(3):378-86. doi: 10.1016/j.bbmt.2012.12.014. Epub 2012 Dec 21.

25.

ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study.

Oschlies I, Lisfeld J, Lamant L, Nakazawa A, d'Amore ES, Hansson U, Hebeda K, Simonitsch-Klupp I, Maldyk J, Müllauer L, Tinguely M, Stücker M, Ledeley MC, Siebert R, Reiter A, Brugières L, Klapper W, Woessmann W.

Haematologica. 2013 Jan;98(1):50-6. doi: 10.3324/haematol.2012.065664. Epub 2012 Jul 6. Review.

26.

Automated measurement of MIB-1 positive area as an alternative to counting in follicular lymphoma.

van der Laak JA, van Engelen N, Melissen M, Hebeda KM.

Cytometry A. 2012 Jun;81(6):527-31. doi: 10.1002/cyto.a.22053. Epub 2012 Apr 12.

27.

Primary bone marrow lymphoma: an uncommon extranodal presentation of aggressive non-hodgkin lymphomas.

Martinez A, Ponzoni M, Agostinelli C, Hebeda KM, Matutes E, Peccatori J, Campidelli C, Espinet B, Perea G, Acevedo A, Mehrjardi AZ, Martinez-Bernal M, Gelemur M, Zucca E, Pileri S, Campo E, López-Guillermo A, Rozman M; International Extranodal Lymphoma Study Group.

Am J Surg Pathol. 2012 Feb;36(2):296-304. doi: 10.1097/PAS.0b013e31823ea106.

PMID:
22251943
28.

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.

Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H.

Haematologica. 2012 Mar;97(3):360-5. doi: 10.3324/haematol.2011.047811. Epub 2011 Nov 4.

29.

Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia.

Koopmans SM, Bot FJ, Lam KH, van Marion AM, de Raeve H, Hebeda KM.

Am J Clin Pathol. 2011 Oct;136(4):618-24. doi: 10.1309/AJCP2UG9SGGWAHUA.

PMID:
21917685
30.

PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.

Norde WJ, Maas F, Hobo W, Korman A, Quigley M, Kester MG, Hebeda K, Falkenburg JH, Schaap N, de Witte TM, van der Voort R, Dolstra H.

Cancer Res. 2011 Aug 1;71(15):5111-22. doi: 10.1158/0008-5472.CAN-11-0108. Epub 2011 Jun 9.

31.

Splenic gas as a result of a non-Hodgkin's lymphoma in a patient with common variable immunodeficiency.

Croles FN, Hebeda KM, Kats-Ugurlu G, Hermans JJ, Bonenkamp HJ, van der Velden WJ.

J Clin Oncol. 2011 Aug 10;29(23):e666-7. doi: 10.1200/JCO.2011.35.6659. Epub 2011 Jun 6. No abstract available.

PMID:
21646607
32.

Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel.

Oschlies I, Burkhardt B, Chassagne-Clement C, d'Amore ES, Hansson U, Hebeda K, Mc Carthy K, Kodet R, Maldyk J, Müllauer L, Porwit A, Schmatz AI, Tinguely M, Abramov D, Wotherspoon A, Zimmermann M, Reiter A, Klapper W.

Am J Surg Pathol. 2011 Jun;35(6):836-44. doi: 10.1097/PAS.0b013e318213e90e.

PMID:
21451365
33.

Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome.

Manders P, Spruijt L, Kets CM, Willems HW, Bodmer D, Hebeda KM, Nagtegaal ID, van Krieken JH, Ligtenberg MJ, Hoogerbrugge N.

Eur J Cancer. 2011 Jun;47(9):1407-13. doi: 10.1016/j.ejca.2010.12.024. Epub 2011 Jan 25.

34.

Biomarkers as disease definition: mantle cell lymphoma as an example.

van Krieken JH, Jansen C, Hebeda KM, Groenen PJ.

Proteomics Clin Appl. 2010 Dec;4(12):922-5.

PMID:
21179891
35.

Protein profiling in pathology: analysis and evaluation of 239 frozen tissue biopsies for diagnosis of B-cell lymphomas.

Jansen C, Feuth T, Raemaekers JM, Rijntjes J, Meijer JW, Westenend PJ, van Baarlen J, van Krieken JH, Hebeda KM, Groenen PJ.

Proteomics Clin Appl. 2010 May;4(5):519-27. doi: 10.1002/prca.200900120. Epub 2010 Feb 26.

PMID:
21137069
36.

Specific intraepithelial localization of mast cells in differentiated vulvar intraepithelial neoplasia and its possible contribution to vulvar squamous cell carcinoma development.

van de Nieuwenhof HP, Hebeda KM, Bulten J, Otte-Holler I, Massuger LF, de Hullu JA, van Kempen LC.

Histopathology. 2010 Sep;57(3):351-62. doi: 10.1111/j.1365-2559.2010.03635.x. Epub 2010 Aug 19.

PMID:
20727018
37.

The role of rituximab in a case of EBV-related lymphoproliferative disease presenting with haemophagocytosis.

Bosman G, Langemeijer SM, Hebeda KM, Raemaekers JM, Pickkers P, van der Velden WJ.

Neth J Med. 2009 Sep;67(8):364-5. No abstract available.

38.

PCR clonality detection in Hodgkin lymphoma.

Hebeda KM, Van Altena MC, Rombout P, Van Krieken JH, Groenen PJ.

J Hematop. 2009 Mar;2(1):34-41. doi: 10.1007/s12308-009-0024-1. Epub 2009 Feb 20.

39.

Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity.

Schraders M, Oeschger S, Kluin PM, Hebeda K, Schuuring E, Groenen PJ, Hansmann ML, van Krieken JH.

Mod Pathol. 2009 Mar;22(3):416-25. doi: 10.1038/modpathol.2008.199. Epub 2009 Jan 9.

41.

Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1.

Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG, van Kessel AG, Yuen ST, van Krieken JH, Leung SY, Hoogerbrugge N.

Nat Genet. 2009 Jan;41(1):112-7. doi: 10.1038/ng.283. Epub 2008 Dec 21.

PMID:
19098912
42.

Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting.

Overbeek LI, Ligtenberg MJ, Willems RW, Hermens RP, Blokx WA, Dubois SV, van der Linden H, Meijer JW, Mlynek-Kersjes ML, Hoogerbrugge N, Hebeda KM, van Krieken JH.

Am J Surg Pathol. 2008 Aug;32(8):1246-51.

PMID:
18677806
43.

Richter's syndrome developing in a patient with adult onset Still's disease.

Geurts DE, van der Velden WJ, Hebeda KM, Raemaekers JM.

Ann Hematol. 2009 Jan;88(1):81-4. doi: 10.1007/s00277-008-0526-4. Epub 2008 Jul 8. No abstract available.

PMID:
18607590
44.

Protein profiling of B-cell lymphomas using tissue biopsies: A potential tool for small samples in pathology.

Jansen C, Hebeda KM, Linkels M, Grefte JM, Raemaekers JM, van Krieken JH, Groenen PJ.

Cell Oncol. 2008;30(1):27-38.

45.

Light fractionation does not enhance the efficacy of methyl 5-aminolevulinate mediated photodynamic therapy in normal mouse skin.

de Bruijn HS, de Haas ER, Hebeda KM, van der Ploeg-van den Heuvel A, Sterenborg HJ, Neumann HA, Robinson DJ.

Photochem Photobiol Sci. 2007 Dec;6(12):1325-31. Epub 2007 Aug 28.

PMID:
18046489
46.

In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model.

Pereira CF, Torensma R, Hebeda K, Kretz-Rommel A, Faas SJ, Figdor CG, Adema GJ.

J Immunother. 2007 Oct;30(7):705-14.

PMID:
17893563
47.

[Recognition of congenital endometrial carcinoma: the importance of family history and investigation of microsatellite instability in the tumour].

Hoogerbrugge N, Overbeek LI, de Hullu J, Kets CM, Hebeda KM, Ligtenberg MJ.

Ned Tijdschr Geneeskd. 2007 Jun 30;151(26):1441-4. Dutch.

PMID:
17633970
48.

Aspergillosis--and a misleading sensitivity result.

van Leer-Buter C, Takes RP, Hebeda KM, Melchers WJ, Verweij PE.

Lancet. 2007 Jul 7;370(9581):102. No abstract available.

PMID:
17617278
49.

Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer.

Overbeek LI, Kets CM, Hebeda KM, Bodmer D, van der Looij E, Willems R, Goossens M, Arts N, Brunner HG, van Krieken JH, Hoogerbrugge N, Ligtenberg MJ.

Br J Cancer. 2007 May 21;96(10):1605-12. Epub 2007 Apr 24.

50.

WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.

Michiels JJ, De Raeve H, Hebeda K, Lam KH, Berneman Z, Schroyens W, Schwarz J.

Leuk Res. 2007 Aug;31(8):1031-8. Epub 2007 Mar 23. Review.

PMID:
17367853

Supplemental Content

Loading ...
Support Center